RBC Lifespan Measurement in Diabetic Children

Screening visit: There will be one screening visit before the study. We will do some blood tests that will determine if the subjects can be in this study. If the subject is qualify, he/she will be asked to return for the following scheduled visits.

Study visit 1: We will draw a small amount of subject's blood from the IV. The study subject's blood will then be marked with biotin. We will give back the subject's blood marked with biotin through IV within 4 to 6 hours. Endotoxin analysis (conducted pre-infusion) and bacterial culture analysis (conducted post-infusion) will be performed. Twenty minutes after the blood transfusion, we will draw blood from the IV. After that, we will take out the IV and the subject can go home.

All follow-up study visits:

The subject will have a study visit 24 hours after receiving blood marked with biotin. After that, the subject will have a clinic visit every 7-10 days. These visits will end when we can no longer find the biotin marked blood cells in the subject's blood. This is expected to be approximately 12 weeks later.

At these visits, we will draw blood and also collect all blood glucose results in the past 7-10 days.

After the study visits are completed, there will be one follow-up visit 4-6 months after the subject receives the biotin marked RBCs. We will draw about 0.25 ml of blood.

Continuous glucose monitoring and HbA1c determination-- We will monitor continuous glucose concentrations throughout the study. This will be accomplished by setting up FreeStyle Libre Pro continuous glucose monitoring (CGM) device for each study subject. In addition, HbA1c will be measured once in the middle of the study (likely visit 6) and in the end of the study (likely visit 12).

Inclusion criteria

• children with either type1 or type 2 diabetes between 4-18 years old

Exclusion criteria

• consumption of biotin supplements or raw eggs within 30 days;
• history of gastrointestinal blood loss;
• heart failure ;
• active viral or bacterial infection;
• hemoglobinopathy;
• prior history of liver disease with transaminases more than 3 times the upper limit of normal for age;
• uncontrolled thyroid disease;
• anemia (whole blood HCT<33);
• history of renal disease (prior serum creatinine more than >1.5 mg/dlL);
• detectable antibody to biotin.